# Synendos Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synendos-therapeutics

- Industry: Biotechnology
- Headquarters: Switzerland
- Website: www.synendos.com
- Total disclosed funding: $26M
- Latest round: Series A (Apr 20, 2021)
- Investors on record: 9

## About

Synendos Therapeutics AG focuses on developing innovative therapies targeting neuropsychiatric disorders through the modulation of the endocannabinoid system, aiming to provide effective solutions for mental health challenges.Founded in 2019 in Switzerland, Synendos Therapeutics AG is dedicated to developing treatments for neuropsychiatric disorders. The company is led by CEO Andrea Chicca and has successfully completed three funding deals. The latest funding round was a Series A, raising CHF 4.000 mn on April 20, 2021, with investments from Ysios Capital Partners. The firm has its headquarters in Switzerland, although specific global office locations are not detailed.Synendos Therapeutics specializes in creating innovative therapies for neuropsychiatric disorders by modulating the endocannabinoid system. The lead product, SYT-510, classified as a Selective Endocannabinoid Re-uptake Inhibitor (SERI), aims to restore natural brain function affected by endocannabinoid deficiencies linked to conditions such as anxiety and PTSD. Currently in clinical development, SYT-510's Phase 1 trials are set to begin in February 2024 after receiving authorization in January 2024, targeting healthcare providers and patients globally.Synendos Therapeutics has raised CHF 24.000 mn through its Series A funding round, reflecting strong confidence from investors. The company collaborates with various pharmaceutical stakeholders to facilitate product development. Revenue generation will involve agreements related to clinical trials, drug development partnerships, and potential licensing of proprietary products. SYT-510 will undergo a structured commercialization process post-clinical trials, with no specific pricing details available at this time.Looking ahead, Synendos Therapeutics plans to expand its preclinical studies for PTSD, utilizing grant funding received in April 2021 from Eureka-Eurostars. The company aims to enhance its proof-of-concept research, and as SYT-510 progresses through clinical trials, it will prepare for market entry strategies. Specific geographic markets for expansion have not been disclosed, but the focus remains on ensuring access to its therapies for those affected by neuropsychiatric conditions.

## Funding rounds

- Series A, Apr 20, 2021, $4.4M — Ysios Capital Partners
- Series A, Nov 12, 2020, $22M — Zürcher Kantonalbank, Kurma Partners, High-Tech Gruenderfonds, Essential Investments, Sunstone Life Science Ventures, Bernina BioInvest AG, Schroder Adveq Management, Lichtsteiner Foundation

## Investors

- Zürcher Kantonalbank — Series A
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Series A
- Essential Investments — Series A
- Sunstone Life Science Ventures (https://capitalatlas.ai/funds/sunstone-life-science-ventures) — Series A
- Bernina BioInvest AG — Series A
- Schroder Adveq Management — Series A
- Lichtsteiner Foundation — Series A
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series A